AllianceBernstein
AST

AllianceBernstein’s Asterias Biotherapeutics Inc. Series A AST Stock Holding History

AllianceBernstein’s Portfolio AST Stock Details AST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-10,400
Closed -$15K – 3214
2018
Q1 		$15K Hold
10,400
– – ﹤0.01% 3015
2017
Q4 		$23K Buy
10,400
+200
+2% +$506 ﹤0.01% 3013
2017
Q3 		$35K Hold
10,200
– – ﹤0.01% 3082
2017
Q2 		$36K Buy
+10,200
New +$33.6K ﹤0.01% 3131

Other funds holding AST

BC
Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NFC
Northeast Financial Consultants Westport, Connecticut $2.45B AUM 15.14% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Thrivent Financial for Lutherans
Thrivent Financial for Lutherans Minneapolis, Minnesota $52.5B AUM 27.12% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Creative Planning
Creative Planning Overland Park, Kansas $147B AUM 18.73% 1-Year Est. Return
ECM
Element Capital Management New York $1.05B AUM 5.05% 1-Year Est. Return
PP
Paloma Partners Greenwich, Connecticut $510M AUM 286.05% 1-Year Est. Return

AllianceBernstein's AST Position: Q2 2018 in Review

AllianceBernstein sold out of Asterias Biotherapeutics Inc. Series A (AST) in Q2 2018, closing a stake of 10,400 shares — an estimated $15K sold.

AllianceBernstein first reported a position in AST in Q2 2017 and held it in 4 quarters. The position peaked at $36K in Q2 2017. 62 funds tracked by Wall St. Rank hold AST as of Q2 2018.

  • AllianceBernstein reported no remaining Asterias Biotherapeutics Inc. Series A position as of Q2 2018 after selling out during the quarter.
  • AllianceBernstein sold 10,400 Asterias Biotherapeutics Inc. Series A shares in Q2 2018, an estimated $15K.
  • AllianceBernstein first reported a position in Asterias Biotherapeutics Inc. Series A in Q2 2017 and held it in 4 quarters.
  • AllianceBernstein's Asterias Biotherapeutics Inc. Series A position peaked at $36K in Q2 2017.
  • 62 funds tracked by Wall St. Rank held Asterias Biotherapeutics Inc. Series A as of Q2 2018.

Based on AllianceBernstein's 13F filing for Q2 2018, filed 13 Aug 2018.